

Ref. No.P-66/2025-26/73  
February 6, 2026

The Relationship Manager,  
Department of Corporate Relations  
BSE Limited,  
P.J. Towers, Dalal Street  
Fort, MUMBAI – 400 001

Dear Sir,

**Subject: Outcome of Board Meeting**

**Reference: Intimation under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 - Submission of Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2025**

Pursuant to the provisions of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (" Listing Regulations ") we wish to inform you that the Board of Directors at their Meeting held today has inter alia, approved the Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended December 31, 2025. In this regard, a copy of the said Financial Results together with Limited Review Reports is enclosed herewith.

These are also being made available on the website of the Company at [www.kilpest.com](http://www.kilpest.com).

The Meeting of the Board of Directors held today commenced at 3:00 P.M. and concluded at 3:55 P.M.

You are requested to kindly take the above information on record.

Thanking You,  
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

**NIKHILKUBER  
DUBEY**

 Digitally signed by NIKHILKUBER  
DUBEY  
Date: 2026.02.06 16:03:26 +05'30'

Nikhil Kuber Dubey  
Whole Time Director  
DIN: 00538049

Encl: As above

**3B BLACKBIO DX LTD**

**(Formerly, Kilpest India Ltd. )**

REGD.OFFICE: 7-C, INDUSTRIAL AREA,GOVINDPURA, BHOPAL-462 023

CIN:L24211MP1972PLC001131

**Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31-12-2025**

(Rs in lakhs)

S.No.	PARTICULARS	QUARTER ENDED			9 MONTHS ENDED		YEAR ENDED
		31-12-2025 (unaudited)	30-09-2025 (unaudited)	31-12-2024 (unaudited)	31-12-2025 (unaudited)	31-12-2024 (unaudited)	31-03-2025 (AUDITED)
I	Revenue from operations	2437.62	2791.16	2343.00	7264.49	6751.00	9052.97
II	Other income	463.14	391.31	301.03	1285.87	1011.80	1502.58
III	<b>Total Income (I + II)</b>	<b>2900.76</b>	<b>3182.47</b>	<b>2644.03</b>	<b>8550.36</b>	<b>7762.80</b>	<b>10555.55</b>
IV	<b>Expenses:</b>						
	Cost of materials consumed	563.39	683.11	570.00	1766.20	1794.00	2475.73
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(17.66)	6.42	(48.12)	(18.11)	(80.49)	(36.45)
	Employee benefits expense	167.57	215.63	145.00	532.01	455.00	620.97
	Finance costs	1.98	1.20	2.38	3.98	6.48	9.68
	Depreciation and amortization expense	22.00	21.50	22.00	65.00	66.00	85.74
	Other expenses	277.77	302.27	179.59	794.39	543.28	1007.13
	<b>Total expenses (IV)</b>	<b>1015.05</b>	<b>1230.13</b>	<b>870.85</b>	<b>3143.47</b>	<b>2784.27</b>	<b>4162.80</b>
V	<b>Profit/(loss) before exceptional items and tax (III - IV)</b>	<b>1885.71</b>	<b>1952.34</b>	<b>1773.18</b>	<b>5406.89</b>	<b>4978.53</b>	<b>6392.75</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit before tax (V - VI)</b>	<b>1885.71</b>	<b>1952.34</b>	<b>1773.18</b>	<b>5406.89</b>	<b>4978.53</b>	<b>6392.75</b>
VIII	Tax expense:						
	(1) Current tax	439.69	458.26	428.34	1219.85	1146.97	1484.57
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	152.23
IX	<b>Profit (Loss) for the period (VII-VIII)</b>	<b>1446.02</b>	<b>1494.08</b>	<b>1344.84</b>	<b>4187.04</b>	<b>3831.56</b>	<b>4755.95</b>
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00	0.00	0.00
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>1446.02</b>	<b>1494.08</b>	<b>1344.84</b>	<b>4187.04</b>	<b>3831.56</b>	<b>4755.95</b>
XII	Paid-up Equity Share capital	856.84	856.84	856.84	856.84	856.84	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	26421.76	26421.76	21921.24	26421.76	21921.24	21921.24
XIV	<b>Earnings per equity share:</b>						
	(1) Basic	16.88	17.44	15.70	48.87	44.72	55.51
	(2) Diluted	16.88	17.44	15.70	48.87	44.72	55.51

FOR AND ON BEHALF OF THE BOARD



*[Signature]*  
**NIKHIL KUBER DUBEY**  
 WHOLE TIME DIRECTOR  
 DIN:00538049

PLACE : BHOPAL  
 DATE: 06.02.2026



***BAHETI & CO.***  
**CHARTERED ACCOUNTANTS**  
24, M.P. NAGAR ZONE II  
BHOPAL 462011  
2763141, 4251535

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to**  
**The Board of Directors**  
**3B BlackBio Dx Limited (Formerly, Kilpest India Limited)**

1. We have reviewed the accompanying statement of unaudited standalone financial results of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) (the "Company") for the quarter ended December 31, 2025 and year to date from April 1, 2025 to December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement

For BAHETI & CO.  
Chartered Accountants  
(Firm Registration No 006287C)

  
(DEEPAK BAHETI)  
Partner



Place: Bhopal  
Date: 06/02/2026

Membership No: 075063

UDIN: 26075063YSXYWN8408



**NOTES ON STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2025**

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on February 6, 2026 after being reviewed by the Audit Committee.
2. The Company's Agrochemical Business is seasonal in nature and the performance can be impacted by weather conditions and cropping pattern.
3. These financial results have been prepared In accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended.
4. All the figures of financials have been rounded off to nearest lakh in rupees.
5. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.
6. The results of the company are available for investors at [www.kilpest.com](http://www.kilpest.com) and [www.bseindia.com](http://www.bseindia.com).
7. Other expenses for the nine months ended December 31,2025 include M&A expenses of Rs 84.06 lac charged in first quarter and Rs 54.54 lac charged in second quarter, i.e. Rs 138.60 lac in total.
8. Other expenses for the third quarter ended December 31, 2025, include CE IVDR (Regulatory) expenses, conference expenses, which is the reason for increase.
9. The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz. Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These codes have been made effective from 21 November 2025. The corresponding all supporting rules under these codes are yet to be notified.

The Company is in the process of evaluating the full impact of these new labour codes announced. The Company has considered the impact for its own employees which is not material to the standalone financial results and is in the process of evaluating other possible impacts including for contract workforce. However, management is of the view that impact, if any, is unlikely to be material.



*[Handwritten signature]*



**3B BlackBio Dx Ltd.**  
(Formerly - Kilpest India Limited)

**Limited Review:**

The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter and nine months ended December 31, 2025 which needs to be explained.

FOR AND ON BEHALF OF THE BOARD

PLACE: BHOPAL  
DATE: 06/02/2026



NIKHIL KUBER DUBEY  
WHOLE TIME DIRECTOR  
DIN: 00538049

**3B BLACKBIO DX LTD**  
(Formerly, Kilpest India Ltd.)

REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023  
CIN:L24211MP1972PLC001131

**Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31-12-2025**

(Rs in lakhs)


S.No.	PARTICULARS	QUARTER ENDED			9 MONTHS ENDED		YEAR ENDED
		31-12-2025 (unaudited)	30-09-2025 (unaudited)	31-12-2024 (unaudited)	31-12-2025 (unaudited)	31-12-2024 (unaudited)	31-03-2025 (AUDITED)
I	Revenue from operations	5034.73	3390.21	2539.25	10648.40	7397.35	9646.86
II	Other income	558.68	550.59	301.30	1540.93	1014.05	1508.36
III	<b>Total Income (I + II)</b>	<b>5593.40</b>	<b>3940.80</b>	<b>2840.55</b>	<b>12189.32</b>	<b>8411.40</b>	<b>11155.22</b>
IV	<b>Expenses:</b>						
	Cost of materials consumed	1367.34	918.76	615.98	2848.02	1879.10	2601.02
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(18.56)	6.42	(48.12)	(18.11)	(80.49)	(36.45)
	Employee benefits expense	821.31	462.79	170.98	1460.64	541.51	732.08
	Finance costs	8.72	3.53	2.38	13.30	6.48	10.85
	Depreciation and amortization expense	37.56	58.20	26.63	123.43	80.54	108.59
	Other expenses	693.06	529.08	293.09	1529.70	838.35	1339.31
	<b>Total expenses (IV)</b>	<b>2909.42</b>	<b>1978.78</b>	<b>1060.94</b>	<b>5956.97</b>	<b>3265.49</b>	<b>4755.40</b>
V	<b>Profit/(loss) before exceptional items and tax (III - IV)</b>	<b>2683.98</b>	<b>1962.02</b>	<b>1779.61</b>	<b>6232.35</b>	<b>5145.91</b>	<b>6399.82</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit before tax (V - VI)</b>	<b>2683.98</b>	<b>1962.02</b>	<b>1779.61</b>	<b>6232.35</b>	<b>5145.91</b>	<b>6399.82</b>
VIII	<b>Tax expense:</b>						
	(1) Current tax	439.69	458.26	430.09	1219.85	1180.35	1478.47
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	152.24
IX	<b>Profit (Loss) for the period (VII-VIII)</b>	<b>2244.29</b>	<b>1503.76</b>	<b>1349.52</b>	<b>5012.50</b>	<b>3965.56</b>	<b>4769.11</b>
	attributable to owners of parent	2172.96	1471.19	1340.34	4903.08	3925.36	4765.17
	attributable to non-controlling interests	71.33	32.57	9.18	109.42	40.20	3.95
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00	0.00	0.00
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>2244.29</b>	<b>1503.76</b>	<b>1349.52</b>	<b>5012.50</b>	<b>3965.56</b>	<b>4769.11</b>
	attributable to owners of parent	2172.96	1471.19	1340.34	4903.08	3925.36	4765.17
	attributable to non-controlling interests	71.33	32.57	9.18	109.42	40.20	3.95
XII	Paid-up Equity Share capital	856.84	856.84	856.84	856.84	856.84	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	26243.65	26243.65	21690.58	26243.65	21690.58	21690.58
XIV	<b>Earnings per equity share:</b>						
	(1) Basic	26.19	17.55	15.75	58.50	46.28	55.66
	(2) Diluted	26.19	17.55	15.75	58.50	46.28	55.66

PLACE : BHOPAL  
DATE : 06.02.2026



FOR AND ON BEHALF OF THE BOARD

*Nikhil Kuber Dubey*  
NIKHIL KUBER DUBEY  
WHOLE TIME DIRECTOR  
DIN:00538049



**BAHETI & CO.**  
**CHARTERED ACCOUNTANTS**  
24, M.P. NAGAR ZONE II  
BHOPAL 462011  
2763141, 4251535

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to**  
**The Board of Directors**  
**3B BlackBio Dx Limited (Formerly, Kilpest India Limited)**

We have reviewed the accompanying Statement of unaudited consolidated financial results of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) (hereinafter referred to as 'the Holding Company') and its subsidiary (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended December 31, 2025 and year to date from April 1, 2025 to December 31, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

The Statement includes the results of the following entities:

- i. 3B BlackBio Dx Limited (Formerly, Kilpest India Limited, Holding)
- ii. TRUPCR Europe Limited (Subsidiary)
- iii. Coris Holding SRL, Belgium

Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The unaudited interim financial results and other unaudited financial information of the subsidiary has not been reviewed by their auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, are based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bhopal  
Date: 06/02/2026

For BAHETI & CO.  
(FRN 006287C)  
Chartered Accountants

(DEEPAK BAHETI)  
Partner



Membership No.075063

UDIN 26075063OJWGGH7775



**NOTES ON CONSOLIDATED UNAUDITED FINANCIAL RESULT FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2025**

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on February 6, 2026 after being reviewed by the Audit Committee.
2. These financial results have been prepared in accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended;
3. The Company has two identified Reportable Business Segments namely Agrochemical and Molecular Diagnostic Kits (Health Care Sector)
4. The summarized figures for M/s 3B BLACKBIO DX LIMITED (FORMERLY, KILPEST INDIA LIMITED) (Both Agrochemicals and Diagnostic Division) as a standalone entity are:

PARTICULARS	QUARTER ENDED			NINE ENDED	MONTHS	YEAR ENDED
	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(AUDITED)
Total Income (Rs Lakhs)	2900.76	3182.47	2644.03	8550.36	7762.80	10555.55
Profit Before Tax (Rs Lakhs)	1885.71	1952.34	1773.18	5406.89	4978.53	6392.75
Profit After Tax* (Rs Lakhs)	1446.02	1494.08	1344.84	4187.04	3831.56	4755.95
Basic Earnings Per Share (Rs)	16.88	17.44	15.70	48.87	44.72	55.51

5. The Consolidated Financials include the Financials of Subsidiary Company also.
6. The Consolidated Financials for the quarter ended December 31, 2025 include CORIS sales of INR 2,400.70 Lakh and profit of INR 700.10 Lakh .





7. The Consolidated Financials for the nine months ended December 31, 2025 include CORIS sales of INR 2,765.74 Lakh and profit of INR 658.20 Lakh, further explained in Slide No. 27 of Investor's Presentation for February 2026; CORIS Performance Review.
8. All the figures of financials have been rounded off to nearest lakh in rupees.
9. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.
10. The Results of the Company are available for investors at [www.kilpest.com](http://www.kilpest.com) and [www.bseindia.com](http://www.bseindia.com)

Limited Review:

The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter and nine months ended December 31, 2025 which needs to be explained.

FOR AND ON BEHALF OF THE BOARD



NIKHIL KUBER DUBEY  
WHOLE TIME DIRECTOR  
DIN: 00538049

PLACE: BHOPAL  
DATE: 06/02/2026

**3B BLACKBIO DX LTD**  
**(Formerly, Kilpest India Ltd. )**  
REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023  
CIN:L24211MP1972PLC001131

**CONSOLIDATED SEGMENTWISE**

**REVENUE AND RESULTS**

(Rs in lakhs)

S.No	Particulars	Quarter ended 31-12-2025 Unaudited	Quarter ended 30-09-2025- Unaudited	Quarter ended 31-12-2024 Unaudited	Nine Months ended 31-12-2025 Unaudited	Nine Months ended 31-12-2024 Unaudited	Year ended 31-03-2025 Audited
1	Segment Revenue						
	(a) Agrochemicals	167.23	347.38	210.95	742.01	917.06	1218.61
	(b) Diagnostic kits	4867.50	3042.83	2328.30	9906.39	6480.29	8428.25
	<b>Total income from operations (net)</b>	<b>5034.73</b>	<b>3390.21</b>	<b>2539.25</b>	<b>10648.40</b>	<b>7397.35</b>	<b>9646.86</b>
2	Segment Results						
	(a) Agrochemicals	(15.70)	27.22	17.45	3.18	47.06	(9.84)
	(b) Diagnostic kits	2708.40	1938.32	1764.54	6242.47	5105.33	6420.50
	<b>Total Segment Profit before Interest and Tax</b>	<b>2692.70</b>	<b>1965.55</b>	<b>1781.99</b>	<b>6245.65</b>	<b>5152.39</b>	<b>6410.66</b>
	Less : Interest Expense						
	(a) Agrochemicals	1.98	1.21	2.38	3.98	6.48	9.68
	(b) Diagnostic kits	6.73	2.32	0.00	9.31	0.00	1.17
	<b>Profit before Tax</b>	<b>2683.98</b>	<b>1962.02</b>	<b>1779.61</b>	<b>6232.35</b>	<b>5145.91</b>	<b>6399.81</b>
3	Segment Assets						
	(a) Agrochemicals	2817.89	2790.51	2810.01	2817.89	2810.01	2718.56
	(b) Diagnostic kits	38443.36	31292.49	25724.47	38443.36	25724.47	26853.28
	<b>Total Segment Assets</b>	<b>41261.25</b>	<b>34083.00</b>	<b>28534.48</b>	<b>41261.25</b>	<b>28534.48</b>	<b>29571.84</b>
4	Segment Liabilities						
	(a) Agrochemicals	322.12	243.51	371.28	322.12	371.28	225.96
	(b) Diagnostic kits	5107.57	3443.30	1570.81	5107.57	1570.81	2245.39
	<b>Total Segment Liabilities</b>	<b>5429.68</b>	<b>3686.81</b>	<b>1942.09</b>	<b>5429.68</b>	<b>1942.09</b>	<b>2471.35</b>
	(a) Agrochemicals	2495.77	2547.00	2438.73	2495.77	2438.73	2492.60
	(b) Diagnostic kits	33335.79	27849.19	24153.66	33335.79	24153.66	24607.89
5	<b>Capital Employed</b>	<b>35831.57</b>	<b>30396.19</b>	<b>26592.39</b>	<b>35831.57</b>	<b>26592.39</b>	<b>27100.49</b>

FOR AND ON BEHALF OF THE BOARD



*(Signature)*  
**NIKHIL KUBER DUBEY**  
**WHOLE TIME DIRECTOR**  
DIN:00538049

PLACE : BHOPAL  
DATE: 06.02.2026